- Report
- April 2025
- 175 Pages
Global
From €3999EUR$4,490USD£3,459GBP
- Report
- April 2025
- 159 Pages
Global
From €5299EUR$5,950USD£4,584GBP
- Report
- January 2025
- 175 Pages
Global
From €3999EUR$4,490USD£3,459GBP
- Clinical Trials
- May 2025
- 1381 Pages
Global
From €3073EUR$3,450USD£2,658GBP
- Report
- January 2024
- 95 Pages
United States
€3117EUR$3,500USD£2,696GBP
Ajovy is a prescription medication used to treat chronic migraine in adults. It is a calcitonin gene-related peptide (CGRP) receptor antagonist, a type of drug that works by blocking the action of CGRP, a chemical involved in migraine headaches. Ajovy is part of a new class of drugs known as Central Nervous System (CNS) drugs, which are designed to treat neurological disorders such as migraine, epilepsy, and Parkinson's disease. Ajovy is the first CGRP receptor antagonist approved by the U.S. Food and Drug Administration (FDA) for the prevention of migraine.
Some companies in the Ajovy market include Teva Pharmaceuticals, Amgen, and Eli Lilly. Show Less Read more